CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $184.8M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.78×, lower than 95% of its Biotechnology peers (median 2.97×)
- Interpretations6 currently firing — 6
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.24BCNY184.80M · vs all stocks (USD)
Trailing P/E
22.61xvs Biotechnology peers
Revenue (TTM)
418.18MCNY62.19M · vs all stocks (USD)
Profit Margin
13.19%vs Biotechnology peers
Beta
0.3840xvs all stocks
52-Week Change
-73.13%vs all stocks
Market Capitalization
1.24BCNY184.80M · vs all stocks (USD)
Enterprise Value
1.07BCNY158.94M · vs all stocks (USD)
Trailing P/E
22.61xvs Biotechnology peers
Price to Sales (TTM)
2.97xvs Biotechnology peers
Price to Book (MRQ)
0.7813xvs Biotechnology peers
Enterprise to Revenue
2.56xvs Biotechnology peers
Enterprise to EBITDA
10.45xvs Biotechnology peers
Profit Margin
13.19%vs Biotechnology peers
Operating Margin
-369.32%vs Biotechnology peers
Return on Assets (TTM)
1.41%vs Biotechnology peers
Return on Equity (TTM)
3.11%vs Biotechnology peers
Revenue (TTM)
418.18MCNY62.19M · vs all stocks (USD)
Revenue per Share (TTM)
2.50CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-92.90%vs Biotechnology peers
Gross Profit (TTM)
163.31MCNY24.29M · vs all stocks (USD)
EBITDA (TTM)
234.43MCNY34.86M · vs all stocks (USD)
Net Income (TTM)
55.16MCNY8.20M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-93.46%vs Biotechnology peers
Operating Cash Flow (TTM)
224.45MCNY33.38M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
98.19MCNY14.60M · vs all stocks (USD)
5-Year Average Dividend Yield
1.11%vs all stocks
Payout Ratio
60.89%vs Biotechnology peers
Minority Interest (Equity)
9.44MCNYFY2025 · Dec 31, 2025Revenue
563.14MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
294.54MCNYFY2025 · Dec 31, 2025Gross Profit
268.60MCNYFY2025 · Dec 31, 2025Operating Income
153.33MCNY22.80M · vs all stocks (USD)
Pre-tax Income
162.30MCNYFY2025 · Dec 31, 2025Income Tax Expense
23.00MCNYFY2025 · Dec 31, 2025Net Income
139.29MCNYFY2025 · Dec 31, 2025EBIT
164.02MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
234.43MCNYFY2025 · Dec 31, 2025Research & Development
47.39MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
35.76MCNYFY2025 · Dec 31, 2025Other Operating Expenses
6.04MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
2.07MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
1.73MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.8600CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.8600CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
167.12MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
167.12MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
139.29MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.43MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
188.82MCNYFY2025 · Dec 31, 2025Free Cash Flow
44.60MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
272.27MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
139.29MCNYFY2025 · Dec 31, 2025Other Non-cash Items
2.58MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
97.53MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-50.58MCNYFY2025 · Dec 31, 2025Capital Expenditures
-144.22MCNYFY2025 · Dec 31, 2025Purchase of Investments
-15.06MCNYFY2025 · Dec 31, 2025Sale of Investments
29.36MCNYFY2025 · Dec 31, 2025Other Investing Activity
-14.10MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-144.02MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
97.86MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-33.28MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-35.87MCNYFY2025 · Dec 31, 2025Other Financing Charges
-32.31MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-3.60MCNYFY2025 · Dec 31, 2025Shares Outstanding
168.31MSharesUpdated Aug 21, 2026Float Shares
85.72MSharesUpdated Aug 21, 2026% Held by Insiders
54.22%vs all stocks
% Held by Institutions
2.14%vs all stocks
Total Cash (MRQ)
386.85MCNY57.53M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.33CNYUpdated Aug 21, 2026Total Debt (MRQ)
206.71MCNY30.74M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1295xvs Biotechnology peers
Current Ratio (MRQ)
3.76xvs Biotechnology peers
Book Value per Share (MRQ)
9.55CNYUpdated Aug 21, 2026Total Assets
1.86BCNY276.55M · vs all stocks (USD)
Total Current Assets
721.72MCNYFY2025 · Dec 31, 2025Total Liabilities
216.16MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.14BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
53.53MCNYFY2025 · Dec 31, 2025Total Current Liabilities
162.63MCNYFY2025 · Dec 31, 2025Cash
273.55MCNYFY2025 · Dec 31, 2025Cash Equivalents
4.68MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
278.23MCNYFY2025 · Dec 31, 2025Accounts Receivable
169.31MCNYFY2025 · Dec 31, 2025Inventory
173.27MCNYFY2025 · Dec 31, 2025Accounts Payable
93.25MCNYFY2025 · Dec 31, 2025Short-term Debt
33.75MCNYFY2025 · Dec 31, 2025Other Current Liabilities
423.01KCNYFY2025 · Dec 31, 2025Long-term Debt
49.53MCNYFY2025 · Dec 31, 2025Common Stock (Book)
168.31MCNYFY2025 · Dec 31, 2025Retained Earnings
613.41MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.64BCNY244.41M · vs all stocks (USD)
Treasury Stock
43.09MCNYFY2025 · Dec 31, 202552-Week Low
6.91CNYUpdated Aug 21, 202652-Week High
31.13CNYUpdated Aug 21, 202652-Week Change
-73.13%vs all stocks
Beta
0.3840xvs all stocks
50-Day MA
9.74CNYUpdated Aug 21, 2026200-Day MA
16.90CNYUpdated Aug 21, 2026Avg 10-Day Volume
2.37MSharesUpdated Aug 21, 2026Avg 30-Day Volume
3.73MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
0.3300CNYUpdated Aug 21, 20266 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
Low RSI With Profitability And Equity Ratio
Recent weekly losses have outpaced gains, on three profitable years and heavy equity.
Reads
Price Below Mean With Profitability And Book Value
Price sits well below its yearly mean, on three profitable years and rising book value.
Reads
Price Below Mean With Profitability And Equity
Price sits well below its yearly mean, profitable three years, and its equity ratio is high for its industry.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.78×, lower than 95% of its Biotechnology peers (median 2.97×)Notable
Price-to-book: 0.78Industry median: 2.97Industry P5: 1.03Peers compared: 261
Financial Health
Altman Z-Score 4.87: safe zoneNotable
Altman Z-Score: 4.87
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $184.8M, lower than 95% of all stocks globallySignificant
Market cap (USD): 184,803,288.404Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
MediWound Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Anika Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Rightongene Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tonix Pharmaceuticals Holding Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Voyager Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
NervGen Pharma Corp.
Tier 1ProductionApproval-Gated PipelineRule
Onward Medical
Tier 1ProductionApproval-Gated PipelineRule
Camp4 Therapeutics Corp.
Tier 1ProductionApproval-Gated PipelineRuleRisk
LENZ Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
TaiGen Biopharmaceuticals Holdings Limited
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Ovctek China Inc.
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
Transaction Co Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesLow RSI With Profitability And Equity RatioCash-Flow Ratios ElevatedMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity
AB Dynamics plc
5 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesLow RSI With Profitability And Equity RatioMulti-Year Revenue, Profit, And Income GrowthPrice Below Mean With Profitability And Book ValuePrice Below Mean With Profitability And Equity